Drug intelligence / Profile preview

PF-06293620

Development stage: Phase 1
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

PF-06293620 is a humanized IgG2Δa monoclonal antibody developed by Pfizer as a glucagon receptor antagonist for the treatment of type 2 diabetes mellitus. It binds to and blocks the human glucagon receptor, thereby inhibiting glucagon signaling. This mechanism reduces hyperglycemia by normalizing dysregulated hepatic glucose production, independent of pancreatic beta cell function. The drug was administered subcutaneously in clinical trials and demonstrated robust lowering of fasting plasma glucose (FPG) and HbA1c in subjects with type 2 diabetes mellitus on stable metformin therapy. Development reached Phase 1 clinical trials but has not progressed further[1][3][4].

Other names: RN909RN-909RN 909

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on PF-06293620.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06293620.

Explore the full profile